The FY15 Defense Appropriations Act
provides $12 million (M) to the Department of Defense Peer Reviewed Alzheimer’s
Research Program (PRARP) to support innovative, high-impact
Alzheimer’s disease research. As directed by the Office of the Assistant
Secretary of Defense for Health Affairs, the Defense Health Agency, Research,
Development, and Acquisition (DHA RDA) Directorate manages and executes the
Defense Health Program (DHP) Research, Development, Test, and Evaluation
(RDT&E) appropriation. The executing agent for the anticipated Program
Announcements/Funding Opportunities is the Congressionally Directed Medical
Research Programs (CDMRP). FY15 PRARP Program Announcements and General
Application Instructions for the following award mechanisms are posted on the Grants.gov website.Applications
submitted to the FY15 PRARP must address one or more of the following
Overarching Challenges and Focus Areas based on the specified mechanism:PRARP FY15
Overarching Challenges:Paucity of
Research Resources: The paucity of research resources to examine the
interrelationship between TBI and subsequent AD for the military and Veteran
communities.Paucity of
Clinical Studies: The paucity of clinical or epidemiological
studies to examine the interrelationship between TBI and subsequent AD for the
military and Veteran communities.Diagnostic
Technologies, Tests, or Devices: The need for technologies,
tests, or devices to detect the progression to AD subsequent to TBI.Quality of
Life: The need for technologies, assessments,
interventions, or devices to benefit individuals living with the symptoms of
TBI and AD.Caregiver
Burden: The need for technologies, assessments,
interventions, or devices with the goal of reducing burden for caregivers of
individuals living with the symptoms of TBI and AD. PRARP FY15
Focus Areas:Genomics/Proteomics/Bioinformatics:
Studies or technologies (e.g., genetic, proteomic, and epigenetic strategies)
intended to characterize neurological change(s) associated with TBI and
subsequent AD. In addition, relevant technologies or tests may be considered
under this focus area.Pathology of
Tau: Novel research and technologies dedicated to
unraveling the basic pathological mechanisms of Tau associated with TBI and AD.Roles of
Non-Neuronal Cells in TBI/AD Pathogenesis: Technologies,
tests, studies, or devices that will examine the roles of astrocytes (or other
non-neuronal cells) in AD neurodegeneration due to TBI.
Imaging:
Development and application of anatomic and molecular imaging strategies to
characterize neurological change associated with TBI and subsequent AD.
Care
Interventions and Quality of Life: Research intended to
stabilize or improve the quality of life of those affected by TBI or AD.
Examples of research in this Focus Area include: identification and management
of co-morbidities and modifiable risk factors (e.g., sleep apnea, obesity);
cognitive training interventions; studies of health and wellness and behavioral
interventions.Caregiver
support: Research intended to reduce the burden of care
on the caregiver for individuals affected by the symptoms of TBI or AD.
Examples of research in this focus area include: Caregiver training,
home-based support, behavioral interventions, and relationship interventions.New for FY15!
Novel Target Identification: Basic research (non-human)
directly leading to the identification of new targets for the development of
existing or new investigational medicines, drugs, or agents. While the CSRA, QUAL, and MRFA mechanisms
can be used to support clinical research, the following is specifically
discouraged under the FY15 PRARP:
Pharmacologic
Interventions: Clinical or Basic research requiring investigational
or U.S. Food and Drug Administration (FDA)-approved drugs or medicines.
Convergence Science Research Award (CSRA) – Preapplication due August
19, 2015Principal
Investigators (PIs) at or above the level of Assistant Professor (or
equivalent) from any field or discipline, who seek to bring their expertise to
address the PRARP’s mission; the research team must demonstrate traumatic brain
injury (TBI)/Alzheimer’s disease (AD) experienceIntent:
Supports research to generate resources and tools, or novel research efforts
for researchers and/or practitioners in health sciences related to the PRARP’s
mission.Applications
should address at least one of the following FY15 Focus Areas:Paucity
of Research ResourcesPaucity
of Clinical StudiesDiagnostic
Technologies, Tests, or Devices Applications
should address at least one of the following FY15 Focus Areas:
- Genomics/Proteomics/Bioinformatics
- Pathology of Tau
- Roles of Non-Neuronal Cells in TBI/AD
Pathogenesis
- New for FY15: Novel
Target Identification
Preliminary
date, while not required, is encouraged.Maximum
funding of $500,000 for direct costs (plus indirect costs)Maximum period
of performance is 3 yearsIndirect costs
may be proposed in accordance with the institution's rate Quality of Life Research Award (QUAL) – Preapplication due August 19,
2015PIs at or
above the level of Assistant Professor (or equivalent) from any field or
discipline, who seek to bring their expertise to address the PRARP’s mission;
Team must demonstrate TBI/AD experience.Intent:
Supports research to reduce the burden on caregivers and affected individuals,
especially in the military and Veteran communities. The research impact
will benefit the military, Veteran, and civilian communities.Applications
must address one or more of the following FY1 Overarching Challenges:
- Quality of life
- Caregiver Burden
Applications
should address at least one of the following FY15 Focus Areas:
- Care Interventions and Quality of Lifer
- Caregiver Support
Preliminary
data, while not required, is encouraged.Maximum
funding of $500,000 for direct costs (plus indirect costs)Maximum period
of performance is 3 yearsIndirect costs
may be proposed in accordance with the institution’s rate agreement Military
Risk Factor Research Award (MRFA) – Preapplication due August 19, 2015Intent: Facilitates
high-impact, systematic, population-based research investigating the
association between TBI and the subsequent development of AD.
Applications
must address one or more of the following FY15 Overarching Challenges:
- Paucity of Research Resources
- Diagnostic Technologies, Tests, or Devices
- Paucity of Clinical Studies
Applications
should address at least one of the following FY15 Focus Areas:
- Genomics/Proteomics/Bioinformatics
- Pathology of Tau
- Roles of Non-Neuronal Cells in TBI/AD
Pathogenesis
- Imaging
Preliminary
data, while not required, is encouraged.Important
Note: Application must detail and demonstrate expedited
access to a well-defined, already identified study cohortMaximum
funding of $5,000,000 for total costsMaximum period
of performance is 5 yearsIndirect costs
may be proposed in accordance with the institution’s rate agreement. All
applications must conform to the final Program Announcement and General Application
Instructions that will be available for electronic downloading from the
Grants.gov website. The application package containing the required forms for
this award mechanism will also be found on Grants.gov. A listing of all USAMRMC funding opportunities
can be obtained on the Grants.gov website by performing a basic search using
CFDA Number 12.420.
A
pre-application is required and must be submitted through the electronic
Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All
applications must conform to the final Program Announcements and General Application Instructions that will be available
for electronic downloading during July 2015 from the Grants.gov website. The application package
containing the required forms for each award mechanism will also be found on
Grants.gov. A listing of all CDMRP funding opportunities can be obtained
on the Grants.gov website by performing a basic search using CFDA Number
12.420. Applications
must be submitted through the federal government’s single-entry portal, Grants.gov.
Requests for email notification of the Program Announcements release may be
sent to help@eBRAP.org. For more
information about the PRARP or other CDMRP-administered programs, please visit
the CDMRP
website (http://cdmrp.army.mil).For further
information and queries, please contact the MRO Research Grants and Contracts
Team (adm-researchgrants.contracts@monash.edu
x
No comments:
Post a Comment